Alex Bofill

"Querido Daniel, cuanto antes usted se de cuenta de esto, mejor: nada en esta cochina vida vale dos duros si no tienes alguien con quien compartirlo."

[Alex Bofill @AlexBofill]

Diuen que tot això és ser roja i separatista i jo només soc una noia ben educada.

Montserrat Roig (1946-1991).

[Pol Turrents @polispol]

La inauguración de la sagrada familia desde la unidad móvil de TV3 con Paulí Subirà @paulitv3D realizando en directo.

[Òscar Andreu @OscarAndreu]

És possible que allà on nosaltres llegim ‘Primer l’amor, després la tècnica’ ells llegeixin ‘Primer el dret de conquesta, després la tècnica de l’extracció’?

[Alex Bofill @AlexBofill]

No ha començat i ja és la pitjor Copa del Món de la història.

[BBC Sport @BBCSport]

Somali referee Omar Artan, who was set to be the first from his country to officiate at the World Cup finals, has been denied entry to the United States.

[Alex Bofill @AlexBofill]

Estat aconfessional 👍

[EL PAÍS @el_pais]

📺 TV en DIRECTO | El Papa lanza un mensaje contra el aborto en el Congreso: "Toda vida debe ser reconocida y custodiada desde su concepción" https://t.co/glQEolZ0pk

[Alex Bofill @AlexBofill]

@kenzaburoarima @Laporteriabtv @beteve @laxarxa Sí, cada dia pensem en això que dius, no dormim.

[Alex Bofill @AlexBofill]

@CEEuropa Honor nois

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Nicholas Hornstein @GIMedOnc]

#ASCO26

This one is special.

This is the hottest paper of 2026 and potentially in the history of pancreatic cancer.

Let’s dive in.

RASolute 302: Daraxonrasib vs investigator’s choice chemotherapy in previously treated metastatic pancreatic cancer
Abstract LBA5 (soon!)
Presentation: May 31, 2026, 3:21-3:33 PM CDT

For decades, pancreatic cancer has been where good ideas go to die.

We have optimized chemotherapy. We have sequenced chemotherapy. We have celebrated modest gains.

But the central driver of PDAC has always been sitting there in plain sight:

RAS.

More than 90% of pancreatic cancers have oncogenic RAS mutations, and until recently, we had essentially nothing direct to do about it.

Daraxonrasib is an oral RAS(ON) multiselective inhibitor targeting the active GTP-bound state of mutant and wild-type RAS.

And in RASolute 302, it delivered.

Quick hits:

📌 Phase 3 international randomized trial 500 patients with previously treated mPDAC Daraxonrasib vs investigator’s choice chemotherapy

🧬 RAS G12 population
91.8% of patients had RAS G12 mutations

📈 OS in RAS G12 population
13.2 vs 6.6 months
HR 0.40
P<0.001

📈 OS in overall population
13.2 vs 6.7 months
HR 0.40
P<0.001

📊 PFS in RAS G12 population
7.3 vs 3.5 months
HR 0.45
P<0.001

📊 PFS in overall population
7.2 vs 3.6 months
HR 0.49
P<0.001

🔥 12-month OS
Overall population: 53.2% vs 17.3%

⚠️ Toxicity matters, but this was not just more efficacy for more toxicity
Grade ≥3 AEs: 61.8% vs 69.6%
TRAEs leading to discontinuation: 1.2% vs 11.2%

This is the kind of survival curve we almost never get to see in pancreatic cancer.

This validates RAS(ON) inhibition in the most RAS-addicted major cancer. It takes a target we have talked about for decades and turns it into a clinically meaningful survival benefit in a randomized phase 3 trial.

The next questions come fast: 1L combinations, maintenance, perioperative disease, sequencing, resistance, toxicity management, and whether this becomes a new backbone.

RAS is here, and it couldn’t have come sooner.

https://t.co/Y4WJRlRRTk

@TheGutonclab @UGrewalMD @TimothyJBrownMD @OncoAlert @Onco_Nexus @ASCO
@NazliDizman @LauraAlderMD @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @DrSAHaddad @jgong15 @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc

[3CatInfo @3CatInfo]

La protesta dels metges puja de to: una trentena d'hospitals deixen de fer hores extres a partir del juny https://t.co/hRapCsMrlY https://t.co/hRapCsMrlY

[Salvador Illa Roca @salvadorilla]

Ho heu demanat i ho fem: ampliem els Préstecs Emancipació de 35 a 40 anys. Fins a 50.000€, 0% d'interès, que es retornaran un cop pagada la hipoteca.

La nostra prioritat és garantir el dret d’accés a l’habitatge i amb polítiques com aquesta fem un pas més per aconseguir-ho.

[Alex Bofill @AlexBofill]

@FCBfemeni 🫡

[Salut @salutcat]

📈 Avui presentem el pressupost de Salut amb fons addicionals per al 2026, el més alt de la història.

🔜 Una inversió per impulsar la transformació del sistema i garantir-ne la sostenibilitat econòmica.

🤝 És un pressupost que posa les persones al centre: per cuidar-les millor, reduir les esperes i reforçar el nostre sistema públic en un moment exigent.

[Ben Jacobs @JacobsBen]

🚨 BREAKING: Barcelona reach an agreement in principle with Newcastle to sign Anthony Gordon. £70m plus bonuses.

Barcelona have pencilled in a medical for this week and anticipate the deal is formalised quickly.

Bayern expected to lose out despite also agreeing terms with Gordon.

Liverpool never made a move despite historical interest.

🤝 @alex_crook

[Primera Federación Versus e-Learning @Primera_RFEF]

🚨 ¡𝗢𝗙𝗜𝗖𝗜𝗔𝗟!

🔥 ¡Estos son los 𝗣𝗟𝗔𝗬𝗢𝗙𝗙𝗦 𝗗𝗘 𝗔𝗦𝗖𝗘𝗡𝗦𝗢 de la temporada 2025/26!

#PrimeraFederación | #VersusELearning

[Sky Sports @SkySports]

Barcelona win their FOURTH Champions League! 🏆🏆🏆🏆

[Metges de Catalunya @metgescatalunya]

🚨 Degoteig d’adhesions a la campanya 'Ni un minut més': diferents serveis d’11 hospitals públics deixaran de fer activitat extra a partir de l’1 de juny
https://t.co/uMqa9okxpe

[Alex Bofill @AlexBofill]

@SDGPerico @AngelFr96830400 Sou tan insignificants, mare meva.

[Alex Bofill @AlexBofill]

Recordo poques setmanes millors que aquesta per ser culer.

[FC Barcelona @FCBarcelona_cat]

EL CLÀSSIC ÉS NOSTRE I SOM ELS CAMPIONS!!!! 🏆

[Alex Bofill @AlexBofill]

@nocontextfooty @QuimMonzo 🍿